Tradipitant - Vanda Pharmaceuticals
Alternative Names: LY-686017; VLY 686Latest Information Update: 27 Aug 2024
At a glance
- Originator Eli Lilly and Company
- Developer Eli Lilly and Company; National Institute on Alcohol Abuse and Alcoholism; Vanda Pharmaceuticals
- Class Anti-inflammatories; Antipruritics; Antivirals; Anxiolytics; Behavioural disorder therapies; Chlorobenzenes; Gastrokinetics; Pyridines; Skin disorder therapies; Small molecules; Triazoles
- Mechanism of Action Neurokinin 1 receptor antagonists; Substance P inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preregistration Gastroparesis
- Phase III Atopic dermatitis; COVID 2019 infections; Motion sickness
- Phase II Dyspepsia; Pruritus
- Discontinued Alcoholism; Social phobia
Most Recent Events
- 18 May 2024 Efficacy results from a phase III trial in Motion Sickness presented at Digestive Disease Week 2024 (DDW-2024)
- 18 May 2024 Updated efficacy data from a phase III trial in Idiopathic Gastroparesis presented at the Digestive Disease Week (DDW-2024)
- 15 May 2024 Efficacy data from the phase III Motion Serifos trial in Motion sickness released by Vanda Pharmaceuticals